Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Zloza

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Journal for Immunotherapy of Cancer|May 16, 2014
Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia virusesAndrew Zloza, Dae Won Kim, Seunghee Kim-Schulze, et al.
Human Gene Therapy|February 4, 2014
Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory moleculesHoward L Kaufman, Dae Won Kim, Seunghee Kim-Schulze, et al.
Frontiers in Oncology|June 13, 2020
Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung CancerTerese Geraghty, Anugraha Rajagopalan, Rabail Aslam, et al.
ACS Biomaterials Science & Engineering|January 13, 2021
Enhancing the Magnitude of Antibody Responses through Biomaterial StereochemistryRajagopal Appavu, Charles B Chesson, Alexey Y Koyfman, et al.
Cancer Immunology, Immunotherapy : CII|October 21, 2016
Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanomaAndrew Zloza, Neal D Dharmadhikari, Erica J Huelsmann, et al.
International Journal of Molecular Sciences|February 25, 2023
Memory Precursors and Short-Lived Effector T cell Subsets Have Different Sensitivities to TGFβJeremy A O'Sullivan, Frederick J Kohlhapp, Andrew Zloza, et al.
Cancer Immunology, Immunotherapy : CII|June 18, 2011
Priming with very low-affinity peptide ligands gives rise to CD8(+) T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppressionJeremy A O'Sullivan, Andrew Zloza, Frederick J Kohlhapp, et al.
Vaccine|December 7, 2013
Antigenic peptide nanofibers elicit adjuvant-free CD8⁺ T cell responsesCharles B Chesson, Erica J Huelsmann, Andrew T Lacek, et al.
Frontiers in Oncology|September 29, 2017
Oncolytic Viruses-Natural and Genetically Engineered Cancer ImmunotherapiesSachin R Jhawar, Aditya Thandoni, Praveen K Bommareddy, et al.
Journal for Immunotherapy of Cancer|March 17, 2016
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II studyHoward L Kaufman, Thomas Amatruda, Tony Reid, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Journal for Immunotherapy of Cancer|May 16, 2014
Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia virusesAndrew Zloza, Dae Won Kim, Seunghee Kim-Schulze, et al.
Human Gene Therapy|February 4, 2014
Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory moleculesHoward L Kaufman, Dae Won Kim, Seunghee Kim-Schulze, et al.
Frontiers in Oncology|June 13, 2020
Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung CancerTerese Geraghty, Anugraha Rajagopalan, Rabail Aslam, et al.
ACS Biomaterials Science & Engineering|January 13, 2021
Enhancing the Magnitude of Antibody Responses through Biomaterial StereochemistryRajagopal Appavu, Charles B Chesson, Alexey Y Koyfman, et al.
Cancer Immunology, Immunotherapy : CII|October 21, 2016
Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanomaAndrew Zloza, Neal D Dharmadhikari, Erica J Huelsmann, et al.
International Journal of Molecular Sciences|February 25, 2023
Memory Precursors and Short-Lived Effector T cell Subsets Have Different Sensitivities to TGFβJeremy A O'Sullivan, Frederick J Kohlhapp, Andrew Zloza, et al.
Cancer Immunology, Immunotherapy : CII|June 18, 2011
Priming with very low-affinity peptide ligands gives rise to CD8(+) T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppressionJeremy A O'Sullivan, Andrew Zloza, Frederick J Kohlhapp, et al.
Vaccine|December 7, 2013
Antigenic peptide nanofibers elicit adjuvant-free CD8⁺ T cell responsesCharles B Chesson, Erica J Huelsmann, Andrew T Lacek, et al.
Frontiers in Oncology|September 29, 2017
Oncolytic Viruses-Natural and Genetically Engineered Cancer ImmunotherapiesSachin R Jhawar, Aditya Thandoni, Praveen K Bommareddy, et al.
Journal for Immunotherapy of Cancer|March 17, 2016
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II studyHoward L Kaufman, Thomas Amatruda, Tony Reid, et al.
Pageof 8